Jaejun Jung, CEO of AriBio, said on Nov. 18 regarding the results of the global Phase 3 trial of oral Alzheimer’s disease treatment AR1001, "AR1001 met the prespecified success criterion for the primary efficacy endpoint in the monotherapy arm of the global Phase 3 trial. Judging the entire trial a failure solely because statistical significance was not achieved in the overall patient population overlooks the trial design and evaluation criteria established in advance."


Jung Jaejun, CEO of AriBio

Jung Jaejun, CEO of AriBio

View original image

The global Phase 3 trial, POLARIS-AD, enrolled 1,535 patients with early Alzheimer’s disease at approximately 230 clinical sites in 13 countries. The trial designated both the overall patient population and the monotherapy arm, consisting of patients not taking existing medications to alleviate Alzheimer’s disease symptoms, as populations for primary efficacy evaluation. Of the overall significance level of 0.05, 0.03 was allocated to the monotherapy arm and 0.02 to the overall patient population. The trial was designed to meet its primary efficacy objective if either group met its prespecified statistical criterion.


Among the 604 patients in the monotherapy arm, AR1001 delayed clinical worsening by 31% compared with placebo at 52 weeks. On the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the placebo group worsened by 1.40 points, compared with 0.96 points in the AR1001 group. The adjusted mean difference was -0.44 points, with a p-value of 0.0266, meeting the prespecified significance level of 0.03.


The company explained that the monotherapy arm was not a group selected after the trial ended to produce a favorable result, but a patient group designated as a key evaluation population before the trial began. Given that patients not taking existing symptom-relief medications showed relatively clear effects in the preceding Phase 2 trial, the monotherapy arm was designated as a key evaluation population in Phase 3.


AriBio shared the trial results with the management of Samjin Pharmaceutical and Fosun Pharma. Fosun Pharma is considering exercising its contractual option early. The company plans to discuss related follow-up procedures with both parties.



Jung said, "The statistically significant clinical results observed in the monotherapy arm are based on objective data, so they need to be assessed in a balanced manner in accordance with the trial design and evaluation criteria. It is regrettable that even objectively established clinical benefits are being viewed negatively."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing